Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors

Modern Pathology

Volumn 25, Issue 7, 2012, Pages 1033-1039

  De Wilde, Roeland F ^a   Heaphy, Christopher M ^a   Maitra, Anirban ^a   Meeker, Alan K ^a   Edil, Barish H ^a   Wolfgang, Christopher L ^a   Ellison, Trevor A ^a   Schulick, Richard D ^a   Molenaar, I Quintus ^b   Valk, Gerlof D ^b   Vriens, Menno R ^b   Rinkes, Inne H M Borel ^b   Offerhaus, G Johan A ^b   Hruban, Ralph H ^a   Matsukuma, Karen E ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

alternative lengthening of telomeres; ATRX; DAXX; MEN 1; multiple endocrine neoplasia 1; pancreatic neuroendocrine tumor

Indexed keywords

DAXX PROTEIN;

ADULT; AGED; ALPHA THALASSEMIA; ARTICLE; CANCER SUSCEPTIBILITY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; GENETIC PREDISPOSITION; GERM LINE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; MICROADENOMA; MULTIPLE ENDOCRINE NEOPLASIA; PANCREATIC NEUROENDOCRINE TUMOR; PHENOTYPE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; TELOMERE HOMEOSTASIS; TUMOR VOLUME; X LINKED MENTAL RETARDATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NEUROENDOCRINE; DNA HELICASES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; MULTIPLE ENDOCRINE NEOPLASIA TYPE 1; NUCLEAR PROTEINS; PANCREATIC NEOPLASMS; PHENOTYPE; TELOMERE; YOUNG ADULT;

EID: 84863474126     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2012.53     Document Type: Article

References (30)

1. Hochwald SN, Zee S, Conlon KC, et al. Prognostic factors in pancreatic endocrine neoplasms: An analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol 2002;20: 2633-2642. (Pubitemid 34575635)
2. Jiao Y, Shi C, Edil BH, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 2011;331: 1199-1203.
3. Heaphy CM, de Wilde RF, Jiao Y, et al. Altered telomeres in tumors with ATRX and DAXX mutations. Science 2011;333:425.
4. Schwartzentruber J, Korshunov A, Liu XY, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 2012;484: 226-231.
5. Anlauf M, Schlenger R, Perren A, et al. Microadenomatosis of the endocrine pancreas in patients with and without the multiple endocrine neoplasia type 1 syndrome. Am J Surg Pathol 2006;30:560-574. (Pubitemid 44265008)
6. Perren A, Anlauf M, Henopp T, et al. Multiple endocrine neoplasia type 1 (MEN1): Loss of one MEN1 allele in tumors and monohormonal endocrine cell clusters but not in islet hyperplasia of the pancreas. J Clin Endocrinol Metab 2007;92:1118-1128. (Pubitemid 46465691)
7. Eubanks PJ, Sawicki MP, Samara GJ, et al. Putative tumor-suppressor gene on chromosome 11 is important in sporadic endocrine tumor formation. Am J Surg 1994;167:180-185. (Pubitemid 24264162)
8. Debelenko LV, Zhuang Z, Emmert-Buck MR, et al. Allelic deletions on chromosome 11q13 in multiple endocrine neoplasia type 1-associated and sporadic gastrinomas and pancreatic endocrine tumors. Cancer Res 1997;57:2238-2243. (Pubitemid 27247044)
9. Zhuang Z, Vortmeyer AO, Pack S, et al. Somatic mutations of the MEN1 tumor suppressor gene in sporadic gastrinomas and insulinomas. Cancer Res 1997;57:4682-4686. (Pubitemid 27468966)
10. Wang EH, Ebrahimi SA, Wu AY, et al. Mutation of the MENIN gene in sporadic pancreatic endocrine tumors. Cancer Res 1998;58:4417-4420. (Pubitemid 28450045)
11. Hessman O, Lindberg D, Skogseid B, et al. Mutation of the multiple endocrine neoplasia type 1 gene in nonfamilial, malignant tumors of the endocrine pancreas. Cancer Res 1998;58:377-379. (Pubitemid 28087391)
12. Hessman O, Lindberg D, Einarsson A, et al. Genetic alterations on 3p, 11q13, and 18q in nonfamilial and MEN 1-associated pancreatic endocrine tumors. Genes Chromosomes Cancer 1999;26:258-264. (Pubitemid 29468347)
13. Gortz B, Roth J, Krahenmann A, et al. Mutations and allelic deletions of the MEN1 gene are associated with a subset of sporadic endocrine pancreatic and neuroendocrine tumors and not restricted to foregut neoplasms. Am J Pathol 1999;154:429-436. (Pubitemid 29094093)
14. Moore PS, Missiaglia E, Antonello D, et al. Role of disease-causing genes in sporadic pancreatic endo-crine tumors: MEN1 and VHL. Genes Chromosomes Cancer 2001;32:177-181.
15. D'adda T, Pizzi S, Azzoni C, et al. Different patterns of 11q allelic losses in digestive endocrine tumors. Hum Pathol 2002;33:322-329. (Pubitemid 34461466)
16. Klimstra DS, Arnold R, Capella C, et al. Neuroendocrine neoplasms of the pancreas. In: Bosman FT, Carneiro F, Hruban RH, Theise ND (eds). WHO classification of tumours of the digestive system. 4th edn. WHO Press: Geneva, Switzerland, 2010, pp 322-326.
17. Heaphy CM, Subhawong AP, Hong SM, et al. Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol 2011;179:1608-1615.
18. Marciniak RA, Cavazos D, Montellano R, et al. A novel telomere structure in a human alternative lengthening of telomeres cell line. Cancer Res 2005;65:2730-2737. (Pubitemid 40490074)
19. Fasching CL, Bower K, Reddel RR. Telomerase-independent telomere length maintenance in the absence of alternative lengthening of telomeres-associated promyelocytic leukemia bodies. Cancer Res 2005;65: 2722-2729. (Pubitemid 40490073)
20. Cerone MA, Autexier C, Londono-Vallejo JA, et al. A human cell line that maintains telomeres in the absence of telomerase and of key markers of ALT. Oncogene 2005;24:7893-7901. (Pubitemid 41715195)
21. Rindi G, Arnold R, Bosman FT, et al. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: Bosman FT, Carneiro F, Hruban RH, Thiese ND (eds). WHO classification of tumours of the digestive system. 4th edn. WHO Press: Geneva, Switzerland, 2010, pp 13-14.
22. Modlin IM, Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer 1997;79:813-829. (Pubitemid 27076348)
23. Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the united states. J Clin Oncol 2008;26:3063-3072.
24. Xue Y, Gibbons R, Yan Z, et al. The ATRX syndrome protein forms a chromatin-remodeling complex with Daxx and localizes in promyelocytic leukemia nuclear bodies. Proc Natl Acad Sci USA 2003;100: 10635-10640. (Pubitemid 37140081)
25. Yokoyama A, Wang Z, Wysocka J, et al. Leukemia proto-oncoprotein MLL forms a SET1-like histone methyltransferase complex with menin to regulate Hox gene expression. Mol Cell Biol 2004;24:5639-5649. (Pubitemid 38787950)
26. Hughes CM, Rozenblatt-Rosen O, Milne TA, et al. Menin associates with a trithorax family histone methyltransferase complex and with the Hoxc8 locus. Mol Cell 2004;13:587-597. (Pubitemid 38299385)
27. Wong LH, Ren H, Williams E, et al. Histone H3.3 incorporation provides a unique and functionally essential telomeric chromatin in embryonic stem cells. Genome Res 2009;19:404-414.
28. Wong LH, McGhie JD, Sim M, et al. ATRX interacts with H3.3 in maintaining telomere structural integrity in pluripotent embryonic stem cells. Genome Res 2010;20:351-360.
29. Lewis PW, Elsaesser SJ, Noh KM, et al. Daxx is an H3.3-specific histone chaperone and cooperates with ATRX in replication-independent chromatin assembly at telomeres. Proc Natl Acad Sci USA 2010;107: 14075-14080.
30. Drane P, Ouararhni K, Depaux A, et al. The deathassociated protein DAXX is a novel histone chaperone involved in the replication-independent deposition of H3.3. Genes Dev 2010;24:1253-1265.